Operating in stealth mode allows biotech companies to protect their intellectual property and maintain focus on R&D without the pressure of external scrutiny. This strategy helps safeguard innovations, particularly in competitive fields, but can also limit visibility, making it harder to attract top-tier talent and investors. To mitigate these challenges, companies must strike a balance between confidentiality and building strategic partnerships, which are crucial for securing resources, scaling operations, and enhancing market credibility.
Our Artem A. Trotsyuk recently explored these dynamics with Willow Shah-Neville in her Labiotech.eu article. You can read it here.
Our Artem A. Trotsyuk recently explored these dynamics with Willow Shah-Neville in her Labiotech.eu article. You can read it here.